Supreme Court of Appeal hands down important judgment on pharma marks
In Adcock Ingram Intellectual Property (Pty) Ltd v Cipla Medpro (Pty) Ltd ((265/2011)  ZASCA 39, March 29 2012), the South African Supreme Court of Appeal has handed down an important judgment for pharmaceutical trademarks. The case reconsidered the notion that pharmaceuticals sold on prescription are less likely to be confused because they are dispensed by trained professionals in regulated circumstances. In doing so, the court questioned the relevance of findings in a 1983 leading case, also involving Adcock Ingram Intellectual Property (Pty) Ltd, in contemporary society.
The marks at issue are Adcock's earlier trademark ZETOMAX and Cipla's ZEMAX mark. The goods in question are those covered by their respective registrations in Class 5 of the Nice Classification (pharmaceuticals) which are, in part, identical to each other. The court was called on to decide whether ZEMAX was wrongly remaining on the register because it offended Section 10(14) of the Trademarks Act (ie, it was so similar to an earlier existing registration that confusion is likely); although Section 10(12) was pleaded based on actual use of the ZETOMAX mark, the case centred on Section 10(14). The lower court had held that there was no likelihood of confusion, primarily because the goods are sold by trained professionals, pharmacists and medical practitioners on prescription, following findings in the 1983 case.
The appeal court first had to correct the lower court on the proper test to be applied. The lower court had erred in applying a test that was confined to considering goods in respect of which the marks were used (as opposed to registered) under Section 10(14). The lower court had thus failed to appreciate that not all Class 5 goods are sold on prescription.
Once the test had been cleared up by the appeal court (in the process approving Sabel v Puma's global appreciation test and the oft-quoted South African judgments of Plascon Evans and Cowbell), it went about analysing whether confusion was likely in circumstances where the notional consumer, in a specialist market for prescription drugs, was argued to be less likely to be confused - Cipla had all but conceded that a likelihood of confusion could occur for all other goods.
The court gave short shrift Cipla's arguments that both the Trademark Registry and the Medical Control Council had approved the name Zemax - accepting, however, that the Trademark Registry's decision held some weight. The court noted that it is "at large to exercise its own discretion".
Both Zemax and Zetomax are Schedule 3 drugs that, generally, can be prescribed only by a medical practitioner and dispensed with by a pharmacist. Accepting that conditions for the sale of prescription drugs significantly reduce the likelihood of confusion stated in the earlier Adcock case, the court then held that:
"[the remark in the same case that it is the] doctor's responsibility as to what a patient should have, and his alone, has a sense of unreality in modern circumstances where patients are expected to play an active role in relation to their own health. It reduced the patient to a passive bystander."
Further, the court held as follows:
"Such an approach is hardly reconcilable with [Section] 8 of the National Health Act 61 of 2003, which gives the patient the right to participate ‘in any decision affecting his or her personal health and treatment’. Patients often discuss their medication among themselves and with their doctors. They exchange information on which product they find most efficacious. This information may then be discussed with their doctors or pharmacists when the issue of substituting a medicine for a generic or the more expensive innovator product is raised. Often they provide the names of their medicines, particularly chronic medication, to the medical practitioners treating them. They discuss the advantages and disadvantages with them. They consider different options. In a case of emergency a Schedule 3 medicine may be sold, for use during a period not exceeding 30 days in accordance with the original prescription, if the pharmacist is ‘satisfied that an authorised prescriber initiated the therapy’ - clearly on information provided by the patient. Whatever the position may have been in 1983, the patient is no longer a passive bystander when treated and receiving prescribed medication.
 The provisions of [Section] 22F of the Medicines and Related Substances Act widen the scope of the enquiry to be made. Section 22F deals with generic substitution or interchangeable multi-source medicines, and, it was submitted, envisages a situation where the patient forms part of the decision-making process thereby increasing the likelihood of deception or confusion."
After analysing a similar position in Canada, the court held as follows:
"The question whether ZEMAX is ‘likely to deceive or cause confusion’, as [Section] 10(14) requires, must be answered with reference, not to the specialised market of prescription medication only, but with reference to the patient as well. The patient is the ultimate consumer whose wishes may not be disregarded and who has a right to participate in any decision concerning his health and treatment. It may well be that there is little likelihood of the medical practitioner or pharmacist being deceived or confused, but the enquiry does not end there."
Having dealt with the notional consumer, the marks ZETOMAX and ZEMAX were compared and held to be confusingly similar.
This judgment is arguably correct:
- The reality is that more and more people do check and question their diagnosis and prescription on the internet, for instance (in fact, a common complaint from doctors).
- Doctors often provide (or should provide) options to their patients (eg, cancer treatments may have different side effects requiring the patients to become more involved in the decision-making process, even if they do not want to).
- There are reports of an increase in abuse of prescribed drugs by pharmacists, meaning that scheduled drugs are sold without a prescription, requiring caution.
- The risk of the consequences of confusion is heightened by the increasing dangers and prevalence of counterfeit drugs in Africa.
- The possibility of including the 'initial interest confusion' doctrine into the infringement tests may well mean that it is irrelevant that the confused patient is then corrected by say, a pharmacist.
Darren Olivier, Adams & Adams, Pretoria
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10